The foot-and-mouth disease virus is a highly contagious and economically devastating virus of cloven-hooved animals, including cattle, buffalo, sheep, and goats, causing reduced animal productivity and posing international trade restrictions. For decades, chemically inactivated vaccines have been serving as the most effective strategy for the management of foot-and-mouth disease. Inactivated vaccines are commercially produced in cell culture systems, which require successful propagation and adaptation of field isolates, demanding a high cost and laborious time. Cell culture adaptation is chiefly indebted to amino acid substitutions in surface-exposed capsid proteins, altering the necessity of RGD-dependent receptors to heparan sulfate macromolecules for virus binding. Several amino acid substations in VP1, VP2, and VP3 capsid proteins of FMDV, both at structural and functional levels, have been characterized previously. This literature review combines frequently reported amino acid substitutions in virus capsid proteins, their critical roles in virus adaptation, and functional characterization of the substitutions. Furthermore, this data can facilitate molecular virologists to develop new vaccine strains against the foot-and-mouth disease virus, revolutionizing vaccinology via reverse genetic engineering and synthetic biology.
Immunosenescence is the decline in immune function with age, which influences cancer progression and treatment outcomes. This process arises from multiple, interconnected molecular and cellular alterations. Among these, mitochondrial dysfunction in aged immune cells may contribute to impaired immune function through altered metabolism, redox imbalance, and inflammatory signaling. This review discusses mitochondrial alterations alongside other age-related mechanisms that shape immune cell function and may promote cancer development. We examine how DNA damage, telomere shortening, epigenetic changes, altered proteostasis, and mitochondrial dysfunction contribute to immune aging and potentially compromise antitumor immunity. The aged tumor microenvironment is characterized by increased immunosuppressive cell populations, persistent inflammatory signaling, and metabolic alterations that can influence tumor development and therapeutic responses. We also examine how aging affects response to current cancer immunotherapies. While some treatments show comparable efficacy in older and younger patients, others may be less effective in the context of age-related immune dysfunction. Older patients may also experience distinct toxicity profiles that require careful clinical management. Understanding how mitochondrial alterations interact with other mechanisms of aging to shape immunosenescence may help identify therapeutic strategies for cancer in older adults. Future approaches may combine interventions targeting mitochondrial fitness, chronic inflammation, and cellular senescence. However, clinical studies specifically designed to include older populations are needed to establish the relevance of these mechanisms in cancer and to guide age-specific therapeutic strategies.